The Union Cycliste Internationale (UCI) announces that it has notified Colombian rider Fabian Hernando Puerta Zapata of an Adverse Analytical Finding (AAF) of boldenone* in a sample collected in the scope of an out-of-competition control on 11 June 2018. The doping control was planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling.

The rider has the right to request and attend the analysis of the B sample. In accordance with UCI Anti-Doping Rules, the rider has been provisionally suspended until the adjudication of the affair. At this stage of the procedure, the UCI will not comment any further.

* Boldenone is classified as Endogenous Anabolic Androgenic Steroids (AAS) and is prohibited when administered exogenously as per the World Anti-Doping Prohibited List.

• This media release was published by the International Cycling Union (UCI) on 14 August 2018. Click here for the original.